Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

• Egile Nagusiak: Hoai‐Thu Thai (Egilea), Kimiko Koiwai (Egilea), Yoshihisa Shitara (Egilea), Hirotaka Kazama (Egilea), Jean‐Baptiste Fau (Egilea), Dorothée Semiond (Egilea), Christine Veyrat‐Follet (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2023-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of serum M‐protein kinetics and its association with p...